KetamineOne Capital Limited (OTCMKTS:KONEF) Stock gains Momentum: Jumps 12% In a Week

Shares of KetamineOne Capital Limited (OTCMKTS:KONEF) have been gained moemntum over the past week with a jump of 12%.

Traders Review

KONEF stock is trading below the 200-Day and 50-Day Moving averages of $0.88 and $0.38 respectively. However, the stock is trading above the 20-Day moving average of $0.31.

Market Reaction

On Wednesday, KONEF stock ended flat at $0.3469 with 100 shares, compared to its average volume of 817 shares. The stock has moved within a range of $0.3469 – 0.3469 after opening trade at $0.3469.

KetamineOne Adds Seattle Location to US Clinical Network

Company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, KetamineOne Capital Limited (OTCMKTS:KONEF) on December 8, 2021, announced engaging Dr. Tami Meraglia for establishing a ketamine infusion clinic in Seattle, Washington.

The new clinic will be operating as Seattle Ketamine Infusions and will be located at 311 West Republican Street.

Dr. Tami focuses on areas of personalized intravenous treatments and is a national best-selling author. Additionally, Dr. Tami is engaged as a media guest on wellness and health topics.

The company will be providing protocol development, training as well as ongoing support for the clinic, with first patient treatments expected at SKI in early 2022.

Adam Deffett, Interim CEO of Ketamine One said that helping Dr. Tami set up a clinic in the Seattle market is a prospective project and the company is keen on sharing and expertise besides gaining from Dr. Tami’s ability to engage with a large national audience.

Deffett added that the company continues to be closer on achieving the goal of becoming a leader in the mental health space across North America.

Ketamine One is working on providing vital infrastructure for developing and delivering breakthrough mental health treatments. Having a network of clinics in North America, the firm has plans on consolidating a highly fragmented industry.  Its wholly-owned contract research division makes it at the forefront of premium clinical research.

Admin

Leave a Reply

Your email address will not be published. Required fields are marked *